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Purpose: Nocturia has a major impact on quality of life and affects 35 
numerous aspects of health. Lifestyle modifications are expected to 36 
be helpful in improving nocturia; however, the efficacy of this 37 
strategy has not been established. The aim of this study is to test 38 
the efficacy of non-drug lifestyle measures as a first step to treat 39 
nocturia and to find factors predictive of the efficacy of the 40 
intervention. 41 
Materials and Methods: We conducted a prospective evaluation on 56 42 
patients treated at three hospitals between 2005 and 2009 for 43 
symptomatic nocturia. The patients were advised to modify their 44 
lifestyle in order to improve nocturia. Lifestyle modifications 45 
consisted of four directives - restriction of fluid intake, refraining 46 
from excess hours in bed, moderate daily exercise and keeping warm 47 
in bed. The frequency volume chart, International Prostate Symptom 48 
Score and Pittsburgh Sleep Quality Index before and 4 weeks after 49 
the intervention were used to evaluate the efficacy of the therapy.  50 
Results: The mean number of nocturnal voids and the nocturnal urine 51 
volume significantly decreased from 3.6 to 2.7 (p < 0.0001) and from 52 
923 ml to 768 ml (p = 0.0005), respectively. Of the 56 patients, 26 53 
(53.1%) showed an improvement of more than one episode. This treatment 54 
was significantly more effective in patients with a larger amount 55 
 3 
of 24 h urine production.  56 
Conclusions: Non-drug lifestyle measures were effective in reducing 57 
the number of nocturia episodes and improving patients' quality of 58 




Nocturia has a major impact on quality of life, affecting numerous 62 
aspects of health, contributing to fatigue, memory deficits, 63 
depression, increased risk of heart disease, and gastrointestinal 64 
disorders.
1-4
 Nocturnal or global polyuria, reduced nocturnal bladder 65 
capacity and sleep disturbance are the possible causes of nocturia.
5,6
 66 
Medical therapy with anticholinergic agents, desmopressin and time 67 
release diuretics is often considered as first line treatment 68 
depending on the diagnosis and underlying cause; however, medication 69 
has a potential risk of adverse events and would also cause problems 70 
with national medical expenditures as the number of patients increase 71 
as a result of aging of the population. Lifestyle modifications such 72 
as fluid restriction and sleep enhancement are expected to be 73 
helpful,
1,2,7
 but effectiveness of this strategy has not been 74 
established. The aim of this study was to test the efficacy of non-drug 75 
lifestyle measures as a first step to treat nocturia. We also sought 76 
to find factors predictive of the efficacy of the intervention. 77 
78 
 5 
Materials and methods 79 
 80 
Of the patients who visited our outpatient clinic with a chief 81 
complaint of nocturia, those with nocturnal frequency of two or more 82 
voids were enrolled in this study. Exclusion criteria were post void 83 
residual volume of more than 50 ml, untreated urogenital malignancies 84 
or renal, cardiac or hepatic failure. The patients who strongly sought 85 
medical treatment were also excluded.  86 
After completing a 72 h frequency volume chart (FVC), the patients 87 
were advised to modify their lifestyle in order to improve nocturia. 88 
Lifestyle modifications consisted of four directives - restriction 89 
of fluid intake, refraining from excess hours in bed, moderate daily 90 
exercise and keeping warm in bed. We paid attention to avoiding 91 
imposing too strict measures on the patients, and gave them an 92 
explanatory brochure to aid their understanding of the procedure. 93 
In the brochure we said, “Examples of lifestyles that can be associated 94 
with nocturia are listed below. If you think one or more are applicable 95 
to you, please follow the appropriate recommendations.” For fluid 96 
restriction, we instructed the patients that daily fluid intake of 97 
2% of the body weight (i.e., 1000 ml for a person weighing 50 kg) 98 
is enough. We also told patients to restrict fluid in particular in 99 
the evening and to avoid excess alcohol or caffeine intake. Secondly, 100 
we explained that the patients should not stay in bed for a long time 101 
 6 
and that excess bedtime hours would make their sleep shallower, 102 
leading to worsening of the nocturia. Thirdly, as an example of 103 
moderate daily exercise, we told the patients "If you can walk, try 104 
to walk 20 minutes a day. Walking in the evening would be more 105 
effective." Finally, we suggested taking a hot water bottle to bed 106 
as one of the methods to keep warm in bed. 107 
  The FVC, International Prostate Symptom Score (IPSS)
8
 and Pittsburgh 108 
Sleep Quality Index (PSQI)
9,10
 before and 4 weeks after the intervention 109 
were used to evaluate the efficacy of the therapy. The Japanese 110 
versions of these questionnaires have been validated previously.
8,10
 111 
Outcomes were defined as excellent (nocturia decreased by ≥ 2 episodes 112 
/ night), improved (nocturia decreased by ≥ 1 episode / night), or 113 
unchanged. We offered further medical therapy to the non-responders. 114 
The PSQI is a self-rated questionnaire for evaluating subjective sleep 115 
quality. The questions are combined to obtain a global score ranging 116 
from 0-21, with higher scores indicating worse sleep quality. The 117 
global score of > 5 is considered to indicate a sleep disorder.
9
 118 
Nocturnal urine volume (NUV) was defined as the total volume of 119 
urine passed during the night including the first morning void.
11
 120 
Nighttime was defined as the period between going to bed with the 121 
intention of sleeping and waking with the intention of rising.
12
 From 122 
the FVC variables, the following measurements were derived as 123 
described elsewhere:
13
 the nocturnal polyuria index (NPi: the ratio 124 
 7 
of NUV to 24 h urine volume); the nocturia index (Ni: a measure of 125 
nocturnal urine overproduction; a higher score indicating a greater 126 
nocturnal urine overproduction); the predicted number of nocturnal 127 
voids (PNV); and the nocturnal bladder capacity index (NBCi: 128 
reflective of nocturnal bladder capacity, a higher score suggesting 129 
diminished NBC). The nighttime to daytime diuresis ratio was 130 
calculated as [NUV(ml) / nighttime(h)] / [(24h urine volume - NUV) 131 
(ml) / (24-nighttime) (h)]. 132 
For statistical analyses, a Wilcoxon signed rank test was used to 133 
compare repeated measurements of variables. Spearman correlation 134 
coefficients were used to examine the relationship between baseline 135 
parameters and the degree of improvement (change in nighttime 136 
frequency). Nominal data were analyzed using the Fisher’s exact test. 137 
Results were considered significant at p < 0.05. Statistical analysis 138 




Data from 56 patients (47 men and nine women) were evaluated. The 143 
mean age was 74.5 ± 5.7 years (range 59-85) and the mean body mass 144 
index was 21.8 ± 3.2 (range 15.0 - 30.9). Underlying medical disorders 145 
included hypertension (13 patients, 23.2 %), diabetes mellitus (12, 146 
21.4 %), cardiac conditions (10, 17.9 %) and sleep apnea (3, 5.4 %). 147 
 8 
Medical prescriptions included alpha-blockers (13, 23.2 %), 148 
cholinergics (2, 3.6 %), anti-cholinergics (10, 17.9 %) for lower 149 
urinary tract symptoms, and diuretics (5, 8.9 %) for cardiac 150 
conditions. We did not change the previously prescribed drugs and 151 
just added the lifestyle modifications. 152 
  Abstracts from the FVC before and after the intervention showed 153 
significant objective improvement in the symptoms as shown in Table 154 
1. The mean number of nocturnal voids and the NUV decreased from 3.6 155 
± 1.1 to 2.7 ± 1.2 ml (p < 0.0001, Fig. 1) and from 923 ± 332 ml to 156 
768 ± 339 ml (p = 0.0005), respectively. The percentage of patients 157 
with improved and excellent responses was 53.1 % and 24.5 %, 158 
respectively. The 24 h frequency of micturition also decreased from 159 
11.6 ± 2.6 to 10.7 ± 2.9 times (p = 0.0065). Analyses of the FVC-derived 160 
variables revealed significant improvement in NPi, Ni and NBCi (Table 161 
1). The proportion of patients with normal NPi (less than 33 % 
12
) 162 
increased from 4% to 20%. The mean nighttime to daytime diuresis ratio 163 
decreased from 1.46 ± 0.38 to 1.32 ± 0.43 (p = 0.0052).  164 
Patient-reported mean number of nocturia episodes (IPSS question 165 
7) and IPSS-QOL (quality of life) score significantly decreased after 166 
the intervention (Table 2). In 31 out of the 56 patients (54.4%), 167 
the nocturia improved (decreased by ≥ 1 points). In 28 (50.0%), the 168 
IPSS-QOL score improved by 1 or more points. There were no significant 169 
changes in the other scores (IPSS 1 through 6) before and after the 170 
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intervention. Analyses of the PSQI revealed that although the PSQI 171 
global score did not show a significant change, the sleep quality 172 
score significantly improved after the intervention. 173 
Of the non-responders 52 % (13 / 25) underwent medical therapy, 174 
which included anti-cholinergics, desmopressin, diuretics, or 175 
non-steroidal anti-inflammatory drugs. Other non-responders 176 
continued the lifestyle modifications instead of taking medicine. 177 
Among the baseline parameters tested, 24 h and nocturnal urine 178 
volume were significantly associated with the degree of improvement 179 
(Fig. 2). In addition, 10 patients (40 %) out of 25 presenting with 180 
a larger volume of 24 h urine production (greater than the median 181 
value) achieved an excellent response as compared to only 2 patients 182 
(8.3 %) out of 24 with less than the median value (Fisher’s exact 183 
test p = 0.018). All 12 patients who achieved an excellent response 184 
were male and none of the female patients showed an excellent response; 185 
however, it is difficult to draw a definite conclusion about the sex 186 
difference on the efficacy of the treatment because of the small number 187 
of female patients. 188 
There was no significant worsening of the health status reported 189 





Nocturia is associated with various kinds of medical conditions such 194 
as overactive bladder, prostatic disease, diabetes mellitus, 195 
cardiovascular disease and sleep disorders.
1
 Therapeutic strategies 196 
include reducing NUV, increasing nocturnal bladder capacity and 197 
treating sleep disorders. Lifestyle modification or behavioral 198 
therapy are often mentioned in the literature, mainly in an attempt 199 
to reduce nocturnal urine volume; however, their efficacy has not 200 
been established and some authors believe that these treatments are 201 
of limited efficacy and that pharmacologic therapy is the only option 202 
for the majority of patients.
6
 In this study, we attempted to evaluate 203 
the efficacy of this strategy by combining four types of lifestyle 204 
modifications. 205 
The first step in our treatment is fluid restriction. Many people, 206 
encouraged by articles in the media, believe that a high water intake 207 
will help to prevent ischemic heart disease or cerebrovascular disease 208 
and they indeed drink a lot of water; however, there is no definite 209 
evidence that stroke or myocardial infarction can be prevented by 210 
increasing the water intake in daily life, and that a high intake 211 
of water will actually decrease blood viscosity.
14
 Reducing fluid 212 
intake has already been recommended in patients whose nocturia is 213 
secondary to nocturnal polyuria;
1,15
 however, there has been no 214 
recommendation stating the actual means of fluid restriction. As total 215 




 and this is roughly equivalent to drinking fluid of 2–2.5% 217 
of body weight, we made a recommendation as described in the Methods 218 
section. 219 
Second, we recommended shortening the time spent in bed to improve 220 
sleep quality. We previously reported that patients with nocturia 221 
spent a significantly longer time in bed than controls.
17,18
  222 
The third measure was to maintain moderate daily exercise. Asplund 223 
and Aberg reported that lack of regular exercise was associated with 224 
an increased number of nocturnal micturition episodes,
19
 and Sugaya 225 
et al. showed the efficacy of walking exercise in the treatment of 226 
nocturia.
20
 By using the protocol of 30 min rapid walking in the evening 227 
or night for 8 weeks, they achieved a significant reduction in the 228 
number of nocturia episodes from 3.3 to 1.9. It is a very useful 229 
behavioral therapy; however, we were afraid that some of the elderly 230 
patients would find difficulty in carrying out this practice. In order 231 
to make the protocol suitable for as many patients as possible 232 
including those with impaired activities of daily living, we made 233 
a recommendation of moderate exercise, where possible, as described 234 
in the Methods section.  235 
Finally, we included a recommendation to keep warm in bed. Cold 236 
exposure is known to increase urine output by inducing "cold diuresis" 237 
through a combination of increased venous return, activation of atrial 238 
natriuretic peptide, decreased levels of antidiuretic hormone and 239 
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renal antidiuretic hormone receptor, and tubular dysfunction.
21,22
 In 240 
our previous study using a self-reported questionnaire on the reasons 241 
for change in night time frequency in patients with symptomatic 242 
nocturia, feeling cold in bed was the third most prevalent answer 243 
next to increased fluid intake and longer duration in bed.
18
 We have 244 
also shown that urinary symptoms including nocturia worsen in winter 245 
in the general population.
23
  246 
The major limitation of our study is the lack of a control group. 247 
Although the gold standard for study design is a randomized controlled 248 
trial, it is difficult to set a control group in this kind of study. 249 
A possible placebo effect and a patient selection bias should 250 
therefore be kept in mind in interpreting the results. Nevertheless, 251 
the objective improvements shown in the FVC analyses strongly support 252 
the efficacy of the therapy. Another weakness of the study is that 253 
we did not structurally obtain the information about the degree to 254 
which the patients actually incorporated the behavioral 255 
recommendations. Although that is an important issue, we did not want 256 
to frustrate the patients by burdening them with writing down the 257 
details of their lifestyle in addition to keeping the FVC and answering 258 
the questionnaires. We decided that the IPSS, PSQI and FVC were the 259 
minimal requirements to evaluate the efficacy of our therapy. It is 260 
therefore difficult to assess which component worked best for each 261 
patient. The most effective and suitable intervention to the given 262 
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baseline conditions should be determined as the next step. Finally, 263 
the long-term effect remains to be confirmed. This point should also 264 
be clarified in the future studies.  265 
In conclusion, the present study demonstrated that lifestyle 266 
measures were effective in improving nocturia, and patients with 267 
larger 24 h urine volume showed a better response. Assessment of FVC 268 
and FVC-derived variables revealed that the number of nocturnal voids 269 
and nocturnal urine volume significantly decreased, and NPi, Ni and 270 
NBCi significantly improved after the intervention; however, bladder 271 
capacity did not show any significant change. This implies that the 272 
efficacy of this therapy is primarily attributable to the reduction 273 




Non-drug lifestyle measures were effective in reducing the number  278 
of nocturia episodes and improving patients' QoL. The effect of this 279 
therapy was shown to result from a reduction in NUV. Patients with 280 




FVC: frequency volume chart 285 
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IPSS: International Prostate Symptom Score 286 
NBCi: nocturnal bladder capacity index 287 
Ni: nocturia index 288 
NPi: nocturnal polyuria index 289 
NUV: nocturnal urine volume 290 
PNV: predicted number of nocturnal voids 291 
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Figure Legends 357 
Fig. 1 — Box plots showing nocturnal frequency before and after the 358 
intervention. Whiskers: 10-90 percentiles; p < 0.001. 359 
Fig. 2 — The relationship between pre-treatment 24 h urine volume 360 
(A) and nocturnal urine volume (B) and decreased number of nocturia 361 
episodes. A: r = 0.3923; p = 0.0102; B: r = 0.3088; p = 0.0466. 362 
 363 
TABLES  
Table 1 — Results of frequency volume chart before and after 
the intervention 
Variables Before After p 
NUV, ml    
  Mean (SD) 923 (332) 768 (339)  
  Median (range) 917 (235-1650) 707 (175-1513) < 0.001 
24 h UV, ml    
  Mean (SD) 1850 (581) 1716 (607)  
  Median (range) 1835 (665-3537) 1705 (675-3084) 0.024 
Nocturnal frequency    
  Mean (SD) 3.6 (1.1) 2.7 (1.2)  
  Median (range) 3.6 (2.0-6.5) 2.8 (0.3-5.0) < 0.001 
24h frequency    
  Mean (SD) 11.6 (2.6) 10.7 (2.9)  
  Median (range) 11.3 (6.3-19.5) 10.0 (5.3-18.5) 0.007 
MVV, ml    
  Mean (SD) 309 (99) 313 (103)  
  Median (range) 300 (50-530) 300 (50-600) 0.65 
NPi    
  Mean (SD) 50.5 (12.2) 45.9 (14.7)  
  Median (range) 48.3 (25.2-75.4) 45.0 (14.6-72.6) 0.004 
Ni    
  Mean (SD) 3.1 (0.9) 2.6 (0.9)  
  Median (range) 2.9 (1.4-5.4) 2.6 (1.2-4.3) < 0.001 
NBCi    
  Mean (SD) 1.5 (0.7) 1.3 (0.6)  
  Median (range) 1.6 (0.2-3.7) 1.2 (0.1-2.8) 0.002 
N/D diuresis ratio    
  Mean (SD) 1.46 (0.38) 1.32 (0.43)  
  Median (range) 1.44 (0.64-2.52) 1.31 (0.58-2.19) 0.005 
NUV = nocturnal urine volume; MVV = maximum voided volume; NPi 
= nocturnal polyuria index; Ni = nocturia index; NBCi= nocturnal 




Table 2 —  Results of IPSS and PSQI before and after the 
intervention 
Variables Before After p 
IPSS - 7    
  Mean (SD) 3.8 (0.8) 3.1 (1.2)  
  Median (range) 4.0 (2.0-5.0) 3.0 (1.0-5.0) <0.001 
IPSS - QOL    
  Mean (SD) 4.6 (1.0) 3.8 (1.4)  
  Median (range) 5.0 (2.0-6.0) 4.0 (0.0-6.0) <0.001 
PSQIG    
  Mean (SD) 6.56 5.95  
  Median (range) 6.0 (0.0-14.0) 5.0 (0.0-14.0) 0.25 
Sleep quality    
  Mean (SD) 2.43 (0.80) 2.10 (0.72)  
  Median (range) 2.0 (1.0-4.0) 2.0 (1.0-4.0) 0.007 
Time in bed, hours    
  Mean (SD) 8.44 (1.1) 8.38 (1.2)  
  Median (range) 8.5 (6.0-10.5) 8.5 (6.2-11.3) 0.99 
IPSS = International Prostate Symptom Score; PSQIG = Pittsburgh 
Sleep Quality Index global score 
 
 



